Coronavirus Update: Novavax Vaccine Shows High Effectiveness Against Variants
Plus: Korea Makes Vaccine Plan, AZ To Produce In Japan
The vaccine is 95.6% effective at preventing infection with the original COVID-19 strain and 85.6% effective at protecting against the B.1.1.7 strain, with an overall level of protection across the strains of 89.3%. Meanwhile, South Korea has drawn up a national vaccination plan and AstraZeneca is set to produce doses of its vaccine in Japan.
You may also be interested in...
Novavax Plays Down EU COVID Vaccine Contract Delay
Investors are anxious about the delay to Novavax’s deal with the EU, and want to know how and when it might file the vaccine with regulators.
Coronavirus Update: Moderna’s Variant-Targeting Vaccine Moves Into Trial, J&J Looks Set For US Authorization
A round up of COVID-19 developments, also including news on the EMA beginning a rolling review of Celltrion's antibody therapy, and progress for Novavax and Moderna in Japan.
Could COVID-19 Variants Upend Global Vaccine Supply Deals?
South Africa recently decided against using AstraZeneca partner Serum Institute’s vaccine for its immunization program, given its low efficacy against the B.1.351 strain. However, certain vaccines have shown higher efficacy. Is this a sign that newer strains of SARS-CoV-2 could upset supply deals and revenue projections for some vaccines?